Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation
Primary efficacy endpoint achieved based on preliminary results from a November 5th data evaluation